Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

ClinicalTrials.gov ID: NCT00772889

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00772889. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).

Study identification

NCT ID
NCT00772889
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
971 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range
19 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 9, 2008 (Type not available)
Primary completion
Dec 15, 2009 (Actual)
Completion
Dec 15, 2009 (Actual)
Last update posted
Jul 31, 2018

2008 – 2009

United States locations

U.S. sites
9
U.S. states
6
U.S. cities
9
Facility City State ZIP Site status
GSK Investigational Site Clearwater Florida 33761 —
GSK Investigational Site Coral Gables Florida 33134 —
GSK Investigational Site Milford Massachusetts 01757 —
GSK Investigational Site Chaska Minnesota 55318 —
GSK Investigational Site Somers Point New Jersey 08244 —
GSK Investigational Site Poughkeepsie New York 12601 —
GSK Investigational Site Carnegie Pennsylvania 15106 —
GSK Investigational Site Erie Pennsylvania 16506 —
GSK Investigational Site Pittsburgh Pennsylvania 15236 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00772889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 31, 2018 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.